Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials

References

• McInnesIBSchettGThe pathogenesis of rheumatoid arthritisN Engl J Med2011365232205221922150039
   PubMed Web of Science ®Google Scholar
• DaikhDISt ClairEWUpdated recommendations for the treatment of rheumatoid arthritis: another step on a long roadArthritis Care Res (Hoboken)201264564865122473919
   PubMed Web of Science ®Google Scholar
• SinghJAFurstDEBharatA2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201264562563922473917
   PubMed Web of Science ®Google Scholar
• YaoZPainterSLFanslowWCHuman IL-17: a novel cytokine derived from T cellsJ Immunol199515512548354867499828
   PubMed Web of Science ®Google Scholar
• KiklyKLiuLNaSSedgwickJDThe IL-23/Th(17) axis: therapeutic targets for autoimmune inflammationCurr Opin Immunol200618667067517010592
   PubMed Web of Science ®Google Scholar
• MiossecPKornTKuchrooVKInterleukin-17 and type 17 helper T cellsN Engl J Med2009361988889819710487
   PubMed Web of Science ®Google Scholar
• ZiolkowskaMKocALuszczykiewiczGHigh levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanismJ Immunol200016452832283810679127
   PubMed Web of Science ®Google Scholar
• ChoMLYoonCHHwangSYEffector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: crosstalk between T cells and synovial fibroblastsArthritis Rheum200450377678415022319
   PubMedGoogle Scholar
• KotakeSUdagawaNTakahashiNIL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclasto-genesisJ Clin Invest199910391345135210225978
   PubMed Web of Science ®Google Scholar
• RazaKFalcianiFCurnowSJEarly rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell originArthritis Res Ther200574R784R79515987480
   PubMed Web of Science ®Google Scholar
• ChabaudMDurandJMBuchsNHuman interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synoviumArthritis Rheum199942596397010323452
   PubMed Web of Science ®Google Scholar
• JoostenLARadstakeTRLubbertsEAssociation of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritisArthritis Rheum200348233934712571842
   PubMedGoogle Scholar
• NistalaKMoncrieffeHNewtonKRVarsaniHHunterPWedderburnLRInterleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbersArthritis Rheum200858387588718311821
   PubMedGoogle Scholar
• ChabaudMFossiezFTaupinJLMiossecPEnhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokinesJ Immunol199816114094149647250
   PubMed Web of Science ®Google Scholar
• GaffenSLRecent advances in the IL-17 cytokine familyCurr Opin Immunol201123561361921852080
   PubMed Web of Science ®Google Scholar
• PappKALeonardiCMenterABrodalumab, an anti-interleukin-17-receptor antibody for psoriasisN Engl J Med2012366131181118922455412
   PubMed Web of Science ®Google Scholar
• MiossecPKollsJKTargeting IL-17 and TH17 cells in chronic inflammationNat Rev Drug Discov2012111076377623023676
   PubMed Web of Science ®Google Scholar
• LubbertsEIL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?Cytokine2008412849118039580
   PubMed Web of Science ®Google Scholar
• GenoveseMCVan den BoschFRobersonSALY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept studyArthritis Rheum201062492993920131262
   PubMed Web of Science ®Google Scholar
• GenoveseMCDurezPRichardsHBEfficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyAnn Rheum Dis201372686386922730366
   PubMed Web of Science ®Google Scholar
• HueberWPatelDDDryjaTRheumatoid Arthritis Study Group, Uveitis Study GroupEffects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitisSci Transl Med201025252ra72
   PubMed Web of Science ®Google Scholar
• PatelDDLeeDMKolbingerFAntoniCEffect of IL-17A blockade with secukinumab in autoimmune diseasesAnn Rheum Dis201372Suppl 2ii116ii12323253932
   PubMed Web of Science ®Google Scholar
• MartinDAChurchillMFlores-SuarezLA phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritisArthritis Res Ther2013155R16424286136
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• FelsonDTAndersonJJBoersMThe American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trialsArthritis Rheum19933667297408507213
   PubMed Web of Science ®Google Scholar
• PrevooMLvan ‘t HofMAKuperHHvan LeeuwenMAvan de PutteLBvan RielPLModified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis Rheum199538144487818570
   PubMed Web of Science ®Google Scholar
• HigginsJGreenSCochrane Handbook for Systematic Reviews of InterventionsChichester West Sussex, UKJohn Wiley & Sons Ltd2011
   Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• KryczekIBruceATGudjonssonJEInduction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasisJ Immunol200818174733474118802076
   PubMed Web of Science ®Google Scholar
• HarperEGGuoCRizzoHTh17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesisJ Invest Dermatol200912992175218319295614
   PubMed Web of Science ®Google Scholar
• ZabaLCSuárez-FariñasMFuentes-DuculanJEffective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJ Allergy Clin Immunol20091245102210.e139519895991
   PubMed Web of Science ®Google Scholar
• LinAMRubinCJKhandpurRMast cells and neutrophils release IL-17 through extracellular trap formation in psoriasisJ Immunol2011187149050021606249
   PubMed Web of Science ®Google Scholar
• CaiYShenXDingCPivotal role of dermal IL-17-producing gammadelta T cells in skin inflammationImmunity201135459661021982596
   PubMed Web of Science ®Google Scholar
• LubbertsEJoostenLAOppersBIL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritisJ Immunol200116721004101311441109
   PubMed Web of Science ®Google Scholar
• NakaeSNambuASudoKIwakuraYSuppression of immune induction of collagen-induced arthritis in IL-17-deficient miceJ Immunol2003171116173617714634133
   PubMed Web of Science ®Google Scholar
• BushKAFarmerKMWalkerJSKirkhamBWReduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion proteinArthritis Rheum200246380280511920418
   PubMed Web of Science ®Google Scholar
• LubbertsEKoendersMIOppers-WalgreenBTreatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosionArthritis Rheum200450265065914872510
   PubMed Web of Science ®Google Scholar
• KoendersMILubbertsEOppers-WalgreenBBlocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1Am J Pathol2005167114114915972960
   PubMed Web of Science ®Google Scholar
• Abdollahi-RoodsazSJoostenLAHelsenMMShift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 productionArthritis Rheum200858123753376419035506
   PubMedGoogle Scholar
• van LentPLGreversLCBlomABStimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritisArthritis Rheum200858123776378719035520
   PubMedGoogle Scholar
• Abdollahi-RoodsazSJoostenLARoelofsMFInhibition of toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritisArthritis Rheum20075692957296717763416
   PubMed Web of Science ®Google Scholar
• RaychaudhuriSPRaychaudhuriSKGenoveseMCIL-17 receptor and its functional significance in psoriatic arthritisMol Cell Biochem20123591–241942921894442
   PubMed Web of Science ®Google Scholar
• JandusCBioleyGRivalsJPDudlerJSpeiserDRomeroPIncreased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritidesArthritis Rheum20085882307231718668556
   PubMed Web of Science ®Google Scholar
• NoordenbosTYeremenkoNGofitaIInterleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritisArthritis Rheum20126419910921968742
   PubMed Web of Science ®Google Scholar
• ShenHXiaLLuJXiaoWInfliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritisJ Investig Med2010587905908
   PubMed Web of Science ®Google Scholar
• KageyamaYKobayashiHKatoNInfliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritisMod Rheumatol200919665766219685204
   PubMed Web of Science ®Google Scholar
• KageyamaYKobayashiHKatoNShimazuMEtanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritisMod Rheumatol200919437237819458908
   PubMed Web of Science ®Google Scholar
• YueCYouXZhaoLThe effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patientsRheumatol Int201030121553155719847432
   PubMed Web of Science ®Google Scholar
• ZhangHLiHLiYIL-17 plays a central role in initiating experimental Candida albicans infection in mouse corneasEur J Immunol201343102671268223843112
   PubMed Web of Science ®Google Scholar
• SchmidtCSuicidal thoughts end Amgen’s blockbuster aspirations for psoriasis drugNat Biotechnol201533989489526348946
   PubMed Web of Science ®Google Scholar
• WilkowskaAPikułaMRynkiewiczAWdowczyk-SzulcJTrzonkowskiPLandowskiJIncreased plasma pro-inflammatory cytokine concentrations after myocardial infarction and the presence of depression during next 6-monthsPsychiatr Pol201549345546426276914
   PubMed Web of Science ®Google Scholar
• GenoveseMCGreenwaldMChoCSA phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitorsArthritis Rheumatol20146671693170424623718
   PubMed Web of Science ®Google Scholar